目的：基于数据挖掘技术探讨中药注射液穴位注射治疗慢性肺系疾病的取穴规律。方法：以中国期刊全文数据库（CNKI）、万方、维普、中国生物医学文献数据库（CBM）为检索库，检索各个数据库自建库以来关于慢性肺系疾病的穴位注射相关文献，建立穴位注射治疗慢性肺系疾病的文献数据库，采用数据挖掘软件对取穴规律进行频数分析、聚类分析、关联分析等。结果：共纳入文献64篇，其中针刺穴位24个，以肺俞使用频率最高（22.66%）；涉及经脉10条，主要归足太阳膀胱经和足阳明胃经；主要中药注射液25种，使用频率最多的是黄芪注射液（21.43%）。聚类分析结果并不理想，但由关联分析可见，腧穴配伍多以肺俞为主穴，配以定喘、肾俞、足三里、天突、丰隆等穴。结论：穴位注射治疗慢性肺系疾病在经脉循行上主要选取足太阳膀胱经和足阳明胃经，一般多选用肺俞、定喘、足三里、肾俞等穴位，采用多穴配伍治疗。

This study was aimed to explore the acupoint law of acupoint injection of traditional Chinese medicine (TCM) injection in the treatment of chronic lung disease based on data mining. Literatures on acupoint injection of chronic lung diseases were retrieved from the China National Knowledge Infrastructure (CNKI), Wanfang, VIP, and Contracts Business Management (CBM) since the establishment of each database. Literature database of acupoint injection for the treatment of chronic lung disease was established. Data mining software was used for frequency analysis, cluster analysis, association analysis, and etc. The results showed that 64 articles were included. There were 24 acupoints. BL-13 Feishu was the one used with the highest frequency (22.66%). There were 10 meridians involved, which were mainly to the bladder meridian and the stomach meridian. There were 25 kinds of main Chinese medicine injections. Astragalus injection was the most frequently used one (21.43%). The result of cluster analysis was not ideal. But the correlation analysis showed that BL-13 was used as the main acupoint in combination with acupoints such as EX Dingchuan, BL-23 Shenshu, ST-36 Zusanli, RN-22 Tiantu, ST-40 Fenglong and so on. It was concluded that acupoint injection in the treatment of chronic lung disease were mainly on the bladder meridian and stomach meridian. The commonly used acupoints were BL-13, EX Dingchuan, ST-36, BL-23 and so on. Multiple acupoints treatment was applied.

国家自然科学基金面上项目（81373579）：基于TGF-β1/Smads信号传导通路的益气养阴活血通络法干预特发性肺纤维化机制研究，负责人：吕晓东；“十二五”国家中医药管理局中医络病重点学科建设项目（2012020108-202）：基于肺络理论特发性肺纤维化证治体系构建：负责人：吕晓东；辽宁省中医临床重点学（专）科服务能力建设项目（2013-LNZYXZK-2）：基于络病理论“内外同治”防治特发性肺纤维化诊疗方案临床疗效研究，负责人：吕晓东。